​

Harmony Biosciences Stock (NASDAQ:HRMY)

ForecastRevenueOwnershipFinancialsChartTranscripts
Harmony Biosciences by TradingView

Previous Close

$33.83

52W Range

$25.52 - $40.87

50D Avg

$31.24

200D Avg

$32.33

Market Cap

$1.96B

Avg Vol (3M)

$817.97K

Beta

0.97

Div Yield

-

HRMY Company Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

268

IPO Date

Aug 19, 2020

Website

HRMY Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22
United States$500.00M$500.00M

Fiscal year ends in Dec 25 | Currency in USD

HRMY Financial Summary

Dec 25Dec 24Dec 23
Revenue$868.45M$714.73M$582.02M
Operating Income$208.47M$190.83M$192.03M
Net Income$158.69M$145.49M$128.85M
EBITDA$208.47M$233.41M$221.51M
Basic EPS$2.76$2.56$2.17
Diluted EPS$2.71$2.51$2.13

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 26May 07, 26 | 12:00 AM
Q4 25Feb 24, 26 | 8:30 AM
Q3 25Nov 04, 25 | 8:30 AM

Peer Comparison

TickerCompany
SIONSionna Therapeutics, Inc.
NUVBNuvation Bio Inc.
ABCLAbCellera Biologics Inc.
IMCRImmunocore Holdings plc
BHVNBiohaven Ltd.
CLDXCelldex Therapeutics, Inc.
VERAVera Therapeutics, Inc.
AUPHAurinia Pharmaceuticals Inc.
MNKDMannKind Corporation
JANXJanux Therapeutics, Inc.